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Abstract
Chronic obstructive pulmonary disease (COPD) is a leading cause of global morbidity and mortality and, whilst smoking
remains the single most important risk factor, COPD risk is heritable. Of 26 independent genomic regions showing
association with lung function in genome-wide association studies, eleven have been reported to show association with
airflow obstruction. Although the main risk factor for COPD is smoking, some individuals are observed to have a high forced
expired volume in 1 second (FEV1) despite many years of heavy smoking. We hypothesised that these ‘‘resistant smokers’’
may harbour variants which protect against lung function decline caused by smoking and provide insight into the genetic
determinants of lung health. We undertook whole exome re-sequencing of 100 heavy smokers who had healthy lung
function given their age, sex, height and smoking history and applied three complementary approaches to explore the
genetic architecture of smoking resistance. Firstly, we identified novel functional variants in the ‘‘resistant smokers’’ and
looked for enrichment of these novel variants within biological pathways. Secondly, we undertook association testing of all
exonic variants individually with two independent control sets. Thirdly, we undertook gene-based association testing of all
exonic variants. Our strongest signal of association with smoking resistance for a non-synonymous SNP was for rs10859974
(P = 2.3461024) in CCDC38, a gene which has previously been reported to show association with FEV1/FVC, and we
demonstrate moderate expression of CCDC38 in bronchial epithelial cells. We identified an enrichment of novel putatively
functional variants in genes related to cilia structure and function in resistant smokers. Ciliary function abnormalities are
known to be associated with both smoking and reduced mucociliary clearance in patients with COPD. We suggest that
genetic influences on the development or function of cilia in the bronchial epithelium may affect growth of cilia or the
extent of damage caused by tobacco smoke.
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Introduction
Chronic obstructive pulmonary disease (COPD) is a leading
cause of global morbidity and mortality [1] and whilst smoking
remains the single most important risk factor, it is also clear that
COPD risk is heritable [2]. The genetics underlying COPD are
still not fully understood although genome-wide association studies
have identified 26 genomic regions showing robust association
with lung function [3–6] and, of these, 11 have also now shown
association with airflow obstruction [7–9]. However, the propor-
tion of the variance accounted for by the 26 common genetic
variants representing these regions remains modest (,7.5% for the
ratio of forced expired volume in 1 second (FEV1) to forced vital
capacity (FVC)) [5].
Although over a quarter of the population with a significant
smoking history go on to develop COPD [10], some individuals
are observed to have preserved lung function as measured by a
normal or high FEV1 despite many years of heavy smoking. We
hypothesised that these ‘‘resistant smokers’’ may harbour rare
variants with large effect sizes which protect against lung function
decline caused by smoking. Identification of these variants, and the
genes that harbour them, could provide further insight into the
mechanisms underlying airflow obstruction.
We undertook whole exome re-sequencing of 100 heavy
smokers (.20 pack years of smoking) who had healthy lung
function when age, sex, height and amount smoked were taken
into account. We employed 3 complementary approaches to
investigate the genetic architecture of the resistant smoker
genotype (Figure 1). Firstly, we screened these 100 ‘‘resistant
smokers’’ for novel rare variants (i.e. not previously identified and
deposited in a public database) with a putatively functional effect
on protein product and tested for enrichment of these novel
variants in functionally related genes and pathways. Secondly,
using a comparision with two independent control sets with exome
re-sequencing data, we looked for signals of association with the
resistant smoker phenotype for individual variants (including
variants of all minor allele frequencies). Thirdly, we looked for
association of the resistant smoker phenotype with the combined
effects of multiple rare and common variants within genes.
We found the strongest evidence of association with resistance
to smoking for a non-synonymous variant in CCDC38, a gene
encoding a coiled-coil domain protein with a role in motor
Author Summary
Very large genome-wide association studies in general
population cohorts have successfully identified at least 26
genes or gene regions associated with lung function and a
number of these also show association with chronic
obstructive pulmonary disease (COPD). However, these
findings explain a small proportion of the heritability of
lung function. Although the main risk factor for COPD is
smoking, some individuals have normal or good lung
function despite many years of heavy smoking. We
hypothesised that studying these individuals might tell
us more about the genetics of lung health. Re-sequencing
of exomes, where all of the variation in the protein-coding
portion of the genome can be measured, is a recent
approach for the study of low frequency and rare variants.
We undertook re-sequencing of the exomes of ‘‘resistant
smokers’’ and used publicly available exome data for
comparisons. Our findings implicate CCDC38, a gene which
has previously shown association with lung function in the
general population, and genes involved in cilia structure
and lung function as having a role in resistance to
smoking.
Figure 1. Flowchart describing each of the 3 main analytical pathways used to explore the genetic architecture of smoking
resistance. Analyses are described in full in the methods. MAF: minor allele frequency.
doi:10.1371/journal.pgen.1004314.g001
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activity, previously identified as showing an association with lung
function. We also show evidence of cytoplasmic expression of
CCDC38 in bronchial columnar epithelial cells. In addition, we
found evidence for an enrichment of novel rare functional variants
in resistant smokers in gene pathways related to cilia structure and
function. Given that abnormalities of ciliary function are already
known to play a role in reduced mucociliary clearance in COPD
sufferers and smokers, these data suggest that genetic factors may
play a significant role in determining the ciliary response of the
airway to inhaled tobacco smoke.
Results
Sample characteristics
100 individuals from the Gedling [11,12] and Nottingham
Smokers cohorts with good lung function (FEV1/FVC.0.7 and %
predicted FEV1.80%) when age, sex, height and smoking history
(.20 pack years) were taken into account were selected as
‘‘resistant smoker’’ cases. Characteristics of the 100 resistant
smoker case samples are shown in Table S1A and Figure S1.
Exome re-sequencing and alignment was undertaken as described
in the methods.
Two independent control sets were used; the robustness of
findings using the primary control set (n = 166) were further
assessed using a secondary control set (n = 230).
Identification of novel putatively functional variants in
cases
We searched for novel variants among the resistant smokers, i.e.
genetic variants which were not observed in either control set and
which were not documented in public databases. Bioinformatic
tools allow for scoring of likely functional impact, including
whether a variant is likely to be ‘‘deleterious’’; here we use the
term ‘‘putatively functional’’ since some variants which have a
deleterious effect on the function of a given gene may result in a
protective phenotype. A total of 24,098 variants which were not
already in databases of known variants or within segmental
duplications were identified with high confidence using two
independent calling algorithms. A total of 6587 coding SNPs
were scored using CAROL (including non-synonymous, loss/gain
of stop codon, synonymous and splice site/UTR variants) and
1722 were predicted as being putatively functional (CAROL
score.0.98) and were within 1533 genes. 16 of these 1533 genes
each contained three novel putatively functional variants (Table
S2) (no gene contained more than three such variants). GBF1
contained three novel putatively functional variants of which one,
chr10:104117872, was identified in two case samples. A further
157 genes each contained 2 novel putatively functional variants
and the remaining 1360 genes contained one novel putatively
functional variant.
In the resistant smokers, there was no overall enrichment or
depletion of novel putatively functional variants among the 26
regions reported to be associated with lung function [5], (16 were
observed, the same number would have been predicted based on
the sequence length of exons) and no novel putatively functional
variants were identified within the CHRNA3/5 region which has
been previously associated with smoking [13] and airflow
obstruction [9].
Eight of the 1722 novel variants predicted to be putatively
functional were identified in .1 case sample. These are listed in
Table S3. ATAD3C contained a novel putatively functional variant
for which six case samples were heterozygous, SHANK2 contained
a novel putatively functional variant for which three cases were
heterozygous, and the remaining six genes each contained such a
variant for which two cases were heterozygous.
One hundred and ninety two Gene Ontology (GO) terms
reached nominal significance for the set of 1533 genes containing
novel putatively functional variants in resistant smoker cases. Of
these, 22 high level GO terms were significant after Bonferroni
correction for multiple testing and are listed in Table 1 [14]. The
most significant GO term was the molecular function term ‘‘motor
activity’’ which describes molecules involved in catalysis of
movement along a polymeric molecule such as a microfilament
or microtubule, coupled to the hydrolysis of a nucleoside
triphosphate. Other related GO terms also feature amongst the
significant signals from this analysis (including ‘‘cytoskeleton’’,
‘‘microtubule motor activity’’, ‘‘myosin complex’’, ‘‘axoneme’’,
‘‘cilium’’ and ‘‘cilium part’’) (Table 1 and Table S4).
Single-variant association testing
We tested for association of known and novel exonic variants
with the resistant smoker phenotype. After exclusion of variants
which were missing in.5% of either cases or controls, 269,822 (of
which 215,747 were listed in dbSNP137) variants remained. Of
the 269,822 variants, 94,138 were exonic and included in further
analyses. Similar distributions of variants across the minor allele
frequency spectrum were observed for the cases, primary, and
secondary controls (results not shown).
After testing for association with resistant smoker status using
primary controls, no SNPs reached genome-wide significance
(P,561027, based on Bonferroni correction for 94,138 tests).
Substantial under-inflation of the test statistics was seen (lamb-
da= 0.6) (Figure 2A), possibly due to the large number of rare
variants (lambda= 0.92 if only variants with MAF.5%
[n= 25,646] were considered, Figure 2B). Twenty exonic SNPs
showed nominal evidence of association with P,1023 (Table 2).
The strongest signal from a non-synonymous SNP was within a
region previously identified as being associated with lung function
[5]. The non-synonymous SNP in CCDC38 (rs10859974,
OR=2.36, P= 2.3461024) is 17.43 kb away from, but statistically
independent of, rs1036429 (intronic, r2 = 0.064) which has
previously shown genome-wide significant association with
FEV1/FVC [5]. SNP rs10859974 itself has shown weak evidence
of association with FEV1/FVC (P= 0.032) [5]. This SNP is
predicted to cause a methionine to valine substitution at protein
position 227; the valine allele is predicted to be protective.
Investigations into CCDC38 expression in bronchial tissue via
immunohistochemistry identified moderate staining of CCDC38
in the cytoplasm of columnar epithelial cells, with weak staining in
the sub-epithelial layer (Figure 3). We found no evidence that
rs10859974 or any of its proxy SNPs (r2.0.3) were lung eQTLs
for CCDC38 itself, although rs11108320 which is intronic in
CCDC38 and in strong LD with rs10859974 (r2 = 1) is an eQTL for
nearby gene NTN4 (significant at 10% False Discovery Rate (FDR)
threshold). Many additional SNPs located near or within CCDC38
and SNRPF were eQTLs for NTN4 (Table S5). Nearby CCDC38
intronic SNPs in weaker LD (r2 = 0.3) with rs10859974 were
eQTLs for SNRPF (Table S5).
The strongest signal of association in the single-variant analysis
was from a synonymous SNP, rs1287467, in SH3BP5 (OR=0.47,
P= 1.4761024) (Table 2). A SNP downstream of SH3BP5
(rs1318937, 1000G CEU MAF=0.108, 16 kb from rs1287467,
r2 = 0.018) has shown evidence of association with alcohol
dependence and alcohol and nicotine co-dependence [15].
Synonymous SNP rs2303296 in ITSN2 was the second strongest
signal of association (OR=0.45, P= 2.3161024) and had
previously shown weak evidence of association with FEV1
Exome Sequencing to Investigate Resistance to Airflow Obstruction
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Table 1. Gene Ontology (GO) terms reaching Bonferroni corrected significance for enrichment amongst the 1533 genes
harbouring novel putatively functional variants in the resistant smokers, using DAVID.
GO ontology term
# genes overlapping
GO term
% of total genes tested
overlapping GO term DAVID EASE P Value
Bonferroni corrected P
value
motor activity 39 2.5 1.78610210 2.0861027
cell adhesion 105 6.8 3.0161028 1.0261024
biological adhesion 105 6.8 3.2261028 1.0961024
cytoskeleton 169 11.0 4.3061028 2.4961025
adenyl nucleotide binding 191 12.5 7.3661027 8.5961024
calcium ion binding 123 8.0 8.6561027 1.0161023
ATPase activity 57 3.7 1.1461026 1.3361023
purine nucleoside binding 191 12.5 2.0861026 2.4361023
nucleoside binding 192 12.5 2.1361026 2.4861023
Axoneme 15 1.0 2.4461026 1.4161023
ATP binding 178 11.6 2.7361026 3.1861023
myosin complex 19 1.2 2.9561026 1.7161023
microtubule motor activity 21 1.4 6.0561026 7.0461023
adenyl ribonucleotide binding 178 11.6 6.2161026 7.2361023
extracellular matrix 53 3.5 1.2261025 7.0661023
Cilium 27 1.8 1.4161025 8.1461023
proteinaceous extracellular matrix 50 3.3 1.4161025 8.1561023
metal ion binding 423 27.6 1.9761025 2.2861022
extracellular matrix part 25 1.6 2.2061025 1.2761022
cation binding 426 27.8 2.3261025 2.6761022
ion binding 431 28.1 2.7461025 3.1561022
cilium part 14 0.9 3.2961025 1.8961022
doi:10.1371/journal.pgen.1004314.t001
Figure 2. QQ plots of single-variant association test statistics for all exonic variants (A) and for exonic variants with MAF.5% (B).
doi:10.1371/journal.pgen.1004314.g002
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(P = 0.02) [5] but was not near to any previously identified
genome-wide significant associations with lung function and has
not shown evidence of association with COPD [9]. Another SNP
in ITSN2, rs6707600 (intronic, 1000 G CEUMAF=0.017, 89 Kb
from rs2303296, r2 = 0.02), has shown some evidence of associ-
ation with antipsychotic response in schizophrenia patients [16].
The second strongest signal from a non-synonymous SNP was
rs4850 in UQCRC2 (OR=4.87, P= 2.461024). There were no
nearby associations reported with any other trait for this gene.
The third strongest signal from a non-synonymous SNP was
rs2297950 (OR=0.51, P = 6.6561024) in CHIT1 which encodes
chitinase 1 (Chit1). The chitinase pathway has been implicated in
asthma and lung function [17] and lung function decline in COPD
patients [18]. Chit1 expression in mice has been shown to be
correlated with severity of bleomycin-induced pulmonary fibrosis
(with overexpression leading to increased severity and Chit12/2
mice exhibiting reduced pulmonary fibrosis) [19].
A non-synonymous SNP in LOXL3, rs17010021, was the only
SNP with an association P,1023 regardless of whether the
primary or the secondary controls were used (Table S6). This
variant had a minor allele frequency of 0.048 and 0.061 in the
primary and secondary control sets respectively, but the minor
allele was not observed in any of the resistant smoker cases.
Synonymous SNP rs1051730, in CHRNA3 (15q25.1), has
previously shown very strong evidence of association with smoking
behaviour (particularly cigarettes per day) [13,20,21]. This SNP
showed weak evidence of association with the resistant smoker
phenotype in our study (P= 0.03 when the secondary control set
was used and P= 0.06 when primary control set was used).
Association results for SNPs within 500 Kb of rs1051730 are in
Table S7.
No nominally significant enrichment of association signals in
known pathways was identified in the exome-wide results of the
single-variant analysis using MAGENTA [22].
Gene-based association testing
SKAT [23] and AMELIA [24] analyses were undertaken to
assess whether multiple variants within a gene collectively showed
evidence of association; these tests are agnostic to whether a given
variant is previously known. Quantile-Quantile plots for SKAT
and AMELIA analyses are shown in Figure 4. Genes with
nominally significant association (P,1023) for SKAT or AMELIA
analysis using the primary controls are shown in Table 3 (results of
SKAT and AMELIA analyses using the secondary controls are
shown in Table S8). No genes showed significant association after
Bonferroni correction for multiple testing (P,0.05/
18000= 2.861026) for either analysis (Table 3 and Table S8).
Since the genes are likely to be correlated (through LD structure or
overlapping reading frames), SKAT provides a resampling
function to control Family Wise Error Rate (FWER). No genes
were significant after controlling FWER=0.05. None of the genes
in Table 3 and Table S8 were within any of the 26 lung function
associated regions [3–5], the CHRNA3/5 smoking-associated
region [13] or SERPINA1 (mutations in which are known to cause
alpha-1-antitrypsin deficiency) [25].
We also checked overlap between the gene-based association
testing and single-variant tests. A signal in TMEM252 (which
showed P,1023 in the SKAT analysis regardless of which control
set was used) was driven by rs117451470, a non-synonymous SNP,
which had P= 2.261023 in the single-variant association analysis
(the other SNP in TMEM252, a singleton novel synonymous
variant, had P= 0.38 in the single-variant analysis). Signals in
UQCRC2 (strongest signal using SKAT), SPATA3D1, PGAP3 and
ADCK2 were also driven by variants with P,1023 in the single-
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variant analysis. Signals from TMX3, IMPG2 and TCOF1 were not
driven by single-variant signals (all SNPs within these genes had
P.0.01 in the single variant analysis). IMPG2 was the strongest
signal from the AMELIA analysis and all 8 SNPs within IMPG2
had no evidence of association in the single-variant analysis
(P.=0.18).
We tested for enrichment of GO terms within the set of genes
showing association with P,0.01 in the SKAT analyses. Ten high
level GO terms reached nominal significance (P,0.05) for the set
of 150 genes identified using SKAT but none were significant after
Bonferroni correction for multiple testing [14].
Discussion
Understanding why some heavy smokers seem to show
resistance to the detrimental effects of cigarette smoke on lung
function should provide further insight into the genetics of lung
function and COPD. We undertook pathway enrichment, single-
Figure 3. Immunohistochemistry staining for Coiled-Coil Domain-Containing Protein 38 (CCDC38) in a normal human bronchial
epithelium at640 magnification. When compared to the unstained isotype control (Rabbit IgG) (A), staining identifies moderate cytoplasmic
expression of CCDC38 particularly in the columnar epithelial cells and the bronchial smooth muscle layer (B). Image representative of three
independent staining procedures.
doi:10.1371/journal.pgen.1004314.g003
Figure 4. QQ plots for SKAT and AMELIA analyses using primary controls.
doi:10.1371/journal.pgen.1004314.g004
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variant association testing and gene-based association testing
analyses on whole exome re-sequencing data from a set of resistant
smokers. Although no individual SNP achieved genome-wide
statistical significance (P,561027), our strongest association signal
for a non-synonymous SNP was in CCDC38; a gene which has
previously shown strong and robust evidence of association with
lung function [5]. The intronic SNP previously shown to be
associated with lung function (FEV1/FVC) and the non-synony-
mous SNP showing nominally significant association with the
resistant smoker phenotype in this study are located close together
(17.4 kb apart) but are not well correlated (the non-synonymous
SNP has previously shown nominally significant evidence
[P,0.05] of association with FEV1/FVC). A conditional analysis
of these two SNPs was consistent with no statistical correlation
between these signals. Although the function of CCDC38 is not yet
well understood, members of the coiled-coil domain protein family
are known to have a role in cell motor activity (e.g. myosin) [26]
and cilia assembly [27,28]. Expression of CCDC38 has been
identified in the human bronchi of two subjects, with strong
cytoplasmic staining in the epithelium and moderate staining in
the airway smooth muscle (Human Protein Atlas [http://www.
proteinatlas.org] [29]: ENSG00000165972). We experimentally
confirmed these findings using immunohistochemistry on lung
sections. We observed moderate cytoplasmic CCDC38 staining in
bronchial columnar epithelial cells and some potential airway
smooth muscle staining. There is no evidence that SNP
rs10859974 is an eQTL for CCDC38 itself, although proxies for
rs10859974 are eQTLs for a nearby downstream gene, NTN4,
encoding Netrin-4 which may play a role in embryonic lung
development [30]. Gene Ontology terms shown to be significantly
enriched among the novel putatively functional variants identified
only in the resistant smokers also pointed to pathways relating to
motor activity and the cytoskeleton, including cilia. Another locus
showing association with lung function (1p36.13, [5]) also contains
a gene encoding a component of cilia (CROCC which encodes
rootletin, another coiled-coil domain protein) and Crocc-null mice
have been shown to have impaired cilia with pathogenic
consequences to the airways [31]. The enrichment of genes
involved in cilia function amongst the results of our analyses
supports the importance of cilia function in lung health. Cilia
abnormalities are known to be associated with smoking [32,33],
asthma [34], and play a role in COPD [35] where reduced cilia
function leads to reduced mucus clearance of the airways.
Improving mucociliary clearance is one of the aims of drug
therapy for chronic bronchitis in COPD patients (reviewed in
[36]).
Impaired cilia function is known to cause a wide range of
diseases (collectively known as ciliopathies) many of which include
pulmonary symptoms [37]. Primary Ciliary Dyskinesia (PCD) is a
rare genetic disorder where respiratory tract cilia function is
impaired leading to reduced (or absent) mucus clearance.
Mutations in genes which encode components of the cilia have
been found to cause several forms of PCD and include the dynein,
axonemal heavy chain encoding genes DNAH11 [38,39] and
DNAH5 [40] within which resistant smoker-specific novel puta-
tively functional variants were identified in this study (2 such
variants were discovered in DNAH11). Whilst PCD affects
resistance to infection and results in bronchiectasis, abnormal
lung function can manifest early in life and progressive airflow
obstruction has been observed in later life, although aggressive
treatment may prevent the latter [41]. Retinitis pigmentosa is a
feature of several ciliopathies, including some with pulmonary
involvement (for example, Alstrom Syndrome). Low frequency
variants in IMPG2 (interphotoreceptor matrix proteoglycan 2)
Table 3. SKAT and AMELIA analysis results using primary controls, ranked by SKAT P value.
SKAT AMELIA Single-Variant
gene Variants SKAT P ,5% MAF AMELIA P# Best Fisher’s P value Description
SPATA3D1 11 3.6261025 9 2.8061025 9.9361024 family with sequence similarity 75,
member D1
UQCRC2 4 7.1561025 0 - 2.4061024 ubiquinol-cytochrome c reductase
core protein II, nuclear gene encoding
mitochondrial protein
UBP1 8 1.1361024 5 6.3661023 1.9361023 upstream binding protein 1 (LBP-1a)
TMEM252 2 4.3861024 0 - 2.2261023 chromosome 9 open reading frame 71
ADCK2 8 4.7661024 7 3.6661024 7.9861024 aarF domain containing kinase 2
PGAP3 2 5.0361024 0 - 9.9361024 post-GPI attachment to proteins 3
CST9L 3 7.1261024 0 - 2.2261023 cystatin 9-like
UPF2 11 9.6061024 8 6.9861024 7.2861023 UPF2 regulator of nonsense
transcripts homolog (yeast)
TMX3 5 2.6061023 5 3.0661024 1.9661022 thioredoxin-related transmembrane
protein 3
LPAL2 9 3.0261023 6 6.5161024 1.3461023 lipoprotein, Lp(a)-like 2, pseudogene
FAM193A 10 3.8261023 10 1.5461024 3.2661023 family with sequence similarity 193,
member A
IMPG2 8 7.5461023 5 ,1.0061027 1.8061021 interphotoreceptor matrix
proteoglycan 2
TCOF1 17 1.3461022 12 4.2961024 1.9661022 Treacher Collins-Franceschetti
syndrome 1
#Only genes with .4 SNPs with MAF,5% were tested by AMELIA.
doi:10.1371/journal.pgen.1004314.t003
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collectively showed strong evidence of association (using AME-
LIA). Variants in IMPG2 are associated with a form of retinitis
pigmentosa [42]. Another retinitis pigmentosa gene, RP1, was
amongst the 16 genes containing 3 novel putatively functional
variants in the resistant smokers. RP1 encodes part of the
photoreceptor axoneme [43], a central component of cilia.
A recent study identified modulators of ciliogenesis using a high
throughput assay of in vitro RNA interference of 7,784 genes in
human retinal pigmented epithelial cells (htRPE) and identified 36
positive modulators and 13 negative modulators of ciliogenesis
[44]. These modulators included many genes which did not
encode structural cilia proteins and thus were not obvious
candidates for a role in cilia function. None of the genes
highlighted by the single-variant or gene-based analyses were
confirmed as modulators of ciliogenesis although ITSN2, which
contained one of the top signals in our single-variant analysis, was
included in the screen and showed suggestive evidence of a positive
role in ciliogenesis but this was not confirmed in a second screen.
Two of the genes found to harbour a novel putatively functional
variant in the resistant smokers were identified as positive
modulators of ciliogenesis: GSN (gelsolin) which is a known cilia
gene with a role in actin filament organisation and AGTPBP1
(ATP/GTP binding protein 1) which has a role in tubulin
modification.
Collectively, our data show an enrichment of novel putatively
functional variants in genes related to cilia structure and function
in resistant smokers. Association between smoking and shorter cilia
has been reported [32]. The largest genome-wide association with
lung function to date supports the notion that the majority of
associated variants, including those associated with COPD risk,
affect lung function development rather than decline in lung
function in adults [5]. If confirmed in other studies, it would be
interesting to assess whether genetic influences on the function of
cilia primarily affect growth or whether these affect more directly
the extent of damage caused by tobacco smoke.
Very large GWAS have identified up to hundreds of common
variants each with a modest effect on a variety of phenotypes.
However, collectively, these still only explain a very modest
proportion of the additive polygenic variance. It has been widely
hypothesised that rare variation may account for some of this
missing variance [45]. Commercially available SNP arrays have
tended to include mostly variants with minor allele frequencies
upwards of 5% and rare variants have not been reliably imputed
from these. Re-sequencing approaches provide the most accurate
platform for the study of exome-wide and genome-wide rare
variation. However, there is increasing evidence that rare variants
may not account for the missing heritability for all traits [46]. Our
study did not find evidence for any individual rare variants with
large effects in any of the known lung function associated loci or
elsewhere in the exome (albeit in a modest overall sample size),
although we did identify significant enrichment of novel rare
variants in sets of genes with known functions in pathways which
are known to have a role in lung health.
For the single variant analyses, we used Fisher’s Exact Test.
Whilst this is an appropriate test to use for small cell counts (for
example, where minor allele counts are low), alternatives have
been recently proposed including the Firth test, and although the
optimal approach in the size of study we undertook is not clear
from the comparisons shown to date, the Fisher’s Exact Test can
be more conservative than the Firth test and this may have had
some impact on the power of the study [47]. Methods for the
analysis of rare variant data are continuing to evolve.
Although this is the first exome re-sequencing study of resistance
to airways obstruction among heavy smokers, our study does have
potential limitations. Sample size was limited both by availability
of individuals with such an extreme phenotype as that we were
able to study, and also by current sequencing costs. We were able
to utilise re-sequencing data available to the scientific community
as control data and therefore maximise the discovery potential of
our resources by re-sequencing to a sufficient sequencing read
depth for confident rare variant calling. By doing so, and selecting
an extreme phenotype group from our sampling frame, we
adopted a suitable design to test whether there was enrichment of
rare variants of large effect in resistant smokers. The same
limitations also impact on the availability of suitable replication
studies. In particular, it would have been desirable to undertake
replication to support the statistically significant findings of the
pathway analysis. However, in the absence of a suitable replication
resource, the prior evidence for the role of cilia in lung health does
lend support to our findings. As it becomes possible to sample and
re-sequence from very large biobanks it should become possible to
circumvent these issues in years to come, particularly if the cost of
sequencing falls.
As limited information was available on smoking status among
the controls, we did not restrict controls to heavy smokers and
there is therefore potential for genetic associations to be driven via
an effect on smoking behaviour. Nevertheless, our design is also
consistent with the detection of association due to primary effect
on airways and previous genome-wide association studies of lung
function not fully adjusted for smoking have detected loci
associated with lung function and COPD which were not
associated with smoking behaviour [4,5]. We saw only a weak
association with variants at the CHRNA3/CHRNA5 locus (the locus
at which variants have shown the strongest effect with smoking
behaviour [13,20,21]).
Misclassification impacts on power; we would have underesti-
mated the power to detect SNP and gene-based associations if the
prevalence of resistance to airways obstruction among heavy
smokers was greater than we assumed. In a cross-sectional study of
this kind, survivor bias could occur if genetic variants influencing
survival were under-represented or over-represented in the
resistant smokers, but as the mean age of the resistant smokers
was 56.4, any survivor bias, if present, is unlikely to have had a
major impact. Finally, although we would expect the allele
frequencies of the control sets we used to be representative of a
general population control set across the vast majority of the
genome, biases could potentially be introduced for any genetic
variants related to the ascertainment strategy of the control sets.
For the main findings we report in this paper, we also present allele
frequencies from a public database (1000 Genomes Project); any
such bias does not explain our main findings.
In the first deep whole exome re-sequencing study of the
resistant smoker phenotype, we have identified an association
signal in a region that has already shown robust association with
lung function (CCDC38) and demonstrate significant enrichment of
novel putatively functional variants in genes related to cilia
structure. These findings provide insights into the mechanisms
underlying preserved lung function in heavy smokers and may
reveal mechanisms shared with COPD aetiology.
Materials and Methods
Ethics statement
The Gedling study was approved by the Nottingham City
Hospital and Nottingham University Ethics committees (MREC/
99/4/01) and written informed consent for genetic study was
obtained from participants. The Nottingham Smokers study was
approved by Nottingham University Medical School Ethical
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Committee (GM129901/) and written informed consent for
genetic study was obtained from participants. The Edinburgh
MR-psychosis sample set was compliant with the UK10K Ethical
Governance Framework (http://www.uk10k.org/ethics.html) and
no restrictions were placed on the use of the genetic data by the
scientific community. For TwinsUK, ethics committee approval
was obtained from Guy’s and St Thomas’ Hospital research ethics
committee. Tissue for immunohistochemistry was from Notting-
ham Health Science Biobank (Nottingham, UK) with the required
ethical approval (08/H0407/1).
For lung eQTL datasets: At Laval, lung specimens were
collected from patients undergoing lung cancer surgery and stored
at the ‘‘Institut universitaire de cardiologie et de pneumologie de
Que´bec’’ (IUCPQ) site of the Respiratory Health Network Tissue
Bank of the ‘‘Fonds de recherche du Que´bec – Sante´’’ (www.
tissuebank.ca). Written informed consent was obtained from all
subjects and the study was approved by the IUCPQ ethics
committee. At Groningen, lung specimens were provided by the
local tissue bank of the Department of Pathology and the study
protocol was consistent with the Research Code of the University
Medical Center Groningen and Dutch national ethical and
professional guidelines (‘‘Code of conduct; Dutch federation of
biomedical scientific societies’’; http://www.federa.org). At Van-
couver, the lung specimens were provided by the James Hogg
Research Center Biobank at St Paul’s Hospital and subjects
provided written informed consent. The study was approved by
the ethics committees at the UBC-Providence Health Care
Research Institute Ethics Board.
Sample selection
100 individuals with prolonged exposure to tobacco smoke and
unusually good lung function (resistant smokers) were selected
from the Gedling and Nottingham Smokers studies, described
below.
The Gedling cohort is a general population sample recruited in
Nottingham in 1991 (18 to 70 years of age, n = 2,633) [11] and
individuals were then followed-up in 2000 (n= 1346) when blood
samples were taken for DNA extraction, and FEV1 and FVC were
measured using a calibrated dry bellows spirometer (Vitalograph,
Buckingham, UK), recording the best of three satisfactory attempts
[12].
The Nottingham Smokers cohort is an ongoing collection in
Nottingham using the following criteria; European ancestry, .40
years of age and smoking history of .10 pack years (currently
n = 538). Lung function measurements (FEV1 and FVC) were
recorded at enrolment using a MicroLab ML3500 spirometer
(Micro Medical Ltd, UK) recording the best of three satisfactory
attempts.
Our inclusion criteria was; aged over 40 with more than 20 pack
years of smoking and no known history of asthma. A total of 184
samples were eligible for this project after further exclusion of
individuals with either FEV1, FVC or FEV1/FVC less than the
Lower Limit Normal (LLN) (based on age, sex and height). We
calculated residuals after adjusting % predicted FEV1 for pack
years of smoking and selected the 100 samples with the highest
residuals for exome re-sequencing (Figure S1).
Primary controls were from the Edinburgh MR-psychosis set
(n= 166) of the UK10K project (http://www.uk10k.org/) and
consisted of subjects with schizophrenia, autism or other psychoses,
and with mental retardation. No additional phenotype information
was available for the primary controls. The TwinsUK secondary
control samples (n= 230) were all unrelated females selected from
the high and low ends of the pain sensitivity distribution of 2500
volunteers from TwinsUK [48,49]. Characteristics of the secondary
controls are given in Table S1B (note that phenotype information
was only available for a subset of the samples). These secondary
controls were not included in the main analyses due to the difference
in exome coverage. Further phenotype information was not
available for either control sample set.
Exome sequencing
For the 100 resistant smoker case samples, DNA was extracted
from whole blood and the Agilent SureSelect All Exon 50 Mb kit
was used for enrichment. The 100 resistant smoker samples were
individually indexed and grouped into 20 pools of 5 samples. Each
pool was sequenced in one lane (20 sequencing lanes in total) using
an Illumina HiSeq2000. Sequences were generated as 100 bp
paired-end reads. Exome-wide coverage of 97 out of 100 samples
was .20 (Figure S2). Three samples had mean sequence depth
coverage ,20, of these, one appeared to have had poor
enrichment (high number of off-target reads), one had a low
overall sequence yield and high number of duplicate reads and one
had a high number of duplicate reads (but good sequence yield).
To preserve power, and because there was no evidence that the
sequence data quality for these samples was lower than for the
other samples, these 3 samples were not excluded from further
analyses.
A total of 166 exomes from the Edinburgh MR-psychosis study:
a subset of the neurodevelopmental disease group of the UK10K
project (http://www.uk10k.org/), were used as primary controls.
These were enriched using the Agilent SureSelect All Exon 50 Mb
kit and sequenced using an Illumina HiSeq2000 to a mean
coverage depth of,70x (75 bp paired-end reads). The sequencing
of the secondary controls from the TwinsUK pain study has been
described elsewhere [49]. In brief, raw sequence data was available
for 230 exomes which had been enriched using the NimbleGen
EZ v2 (44 Mb) array and sequenced on an Illumina HiSeq2000 to
a mean depth of coverage of 71x (90 bp paired-end reads).
Sequence alignment
The sequence alignment of the primary control exomes has
been described elsewhere (http://www.uk10k.org/). The 100
resistant smoker case exomes and 230 TwinsUK controls were
aligned using BWA v0.6.1 [50] with -q15 for read-trimming.
Samtools v0.1.18 [51] was used to convert sort, remove duplicates
and index the alignment .bam files. GATK v1.4-30 [52] was used
to undertake local realignment around indels and to recalibrate
quality scores for all 3 datasets.
Identification of novel putatively functional case-only
variants
In order to identify novel variant calls in the 100 resistant
smoker exomes, GATK and SAMtools mpileup were run on a per
sample basis for all 100 exomes. Only bases with a base quality
score .20 were included. The variants called were then compared
with dbSNP137, 1000 Genomes Project (1000G) and NHLBI
Exome Sequencing Project calls and all known variants were
excluded in order to identify novel rare variants which were
unique to the 100 resistant smoker exomes. The novel GATK
variant calls were then excluded if they had a Phred scaled
probability (QUAL) score ,30, quality by unfiltered depth (non-
REF) (QD) ,5, largest contiguous homopolymer run of the
variant allele in either direction .5, strand bias .20.1 or Phred-
scaled P value using Fisher’s Exact Test to detect strand bias .60.
The novel SAMtools mpileup variants were excluded if they had a
QUAL,30, mapping quality ,25 or genotype quality ,25.
Variants called at sites with a depth of coverage less than 4 or
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greater than 2000 were also excluded. The intersect of variants
which were identified and passed filtering using both GATK and
SAMtools mpileup was taken forward for further analysis.
CAROL (http://www.sanger.ac.uk/resources/software/carol/)
was used to predict the consequence of all coding variants. This
method combines the results of the functional scoring tools SIFT
and Polyphen2. SNPs were predicted as being putatively
functional if they had CAROL score.0.98. Amino acid changes
were predicted using ENSEMBL.
Variant calling and QC across cases and controls
For each comparison (resistant smoker cases vs. primary controls
and resistant smoker cases vs. secondary controls), variant calling
was undertaken across cases and controls together using the GATK
v1.5-20 Unified Genotyper. Only bases with a base quality score
.20 were included. Coverage was down-sampled to 30 (reads are
drawn at random where coverage is greater than 30). This was done
to improve comparability between cases and controls and to speed
up computation. A minimum QUAL of 30 was used as the
threshold for calls. The GATK VQSR approach was used to filter
variants across all samples. Variants with QUAL,30 and
VQSLOD score equivalent to truth,=99.9 were excluded
(VQSLOD score,2.2989). Only single nucleotide polymorphism
variants (SNPs) were called. There was .99% genotype concor-
dance with genotype array data (Illumina 660k) for ,5000 exonic
SNPs with MAF.5% in the 100 resistant smokers.
Association analyses
Single-variant association testing was undertaken using the
Fisher’s exact test for a comparison of resistant smoker cases and
primary controls. A secondary comparison of the resistant smoker
cases and the secondary controls was also undertaken although
results were interpreted with caution due to disparity of the exome
coverage at the pre-sequencing enrichment stage between the
cases and secondary controls. Two approaches to analyse the
effect of multiple variants within genes were used: SKAT (v0.92)
[23] and AMELIA [24]. Variants were assigned to RefSeq genes
using Annovar [53]: a total of 16439 genes were identified as
containing variants in the resistant smoker cases vs. primary
controls analysis. Analysis with SKAT was undertaken using
default weighting to account for the assumption that rare variants
are likely to have bigger effect sizes.
An alternative method, AMELIA [24], was run using a subset of
the variants with MAF,5%. A total of 18182 genes were
identified as containing variants (with MAF,5%), of which
7516 contained more than 4 variants and so could be reliably
tested by AMELIA.
For both SKAT and AMELIA, only variants which were
annotated as exonic, 59UTR or 39UTR were included.
Power calculations
Power estimates for the identification of novel putatively
functional variants in cases only, single-variant association tests
and SKAT analysis were undertaken.
For a given variant unique to, and with a minor allele frequency
of 0.005 in, resistant smokers, the probability of identifying at least
one copy of the minor allele in 100 such individuals is 0.63 (0.86
for a minor allele frequency of 0.01).
Estimates of power for the single-variant association tests were
undertaken for a sample size of 100 cases (resistant smokers) and
166 controls assuming a prevalence of the resistant smoker
phenotype of 2% in the controls. Power calculations for detecting
single variants were undertaken using Quanto and are shown in
Figure S3. As an example, power to detect a variant with an allele
frequency of 0.01 and an OR of 10 would be 10% for an alpha
level of 561028, and 81% for an alpha level of 0.001.
SKAT power calculations were run using the R package SKAT.
The simulated dataset that the R package provides based on the
coalescent populations genetic model was used to assess LD and
MAF. The ‘‘Log’’ option was used to specify that the logOR
distribution varies with allele frequency (logOR increases as minor
allele frequency decreases), the effect size of each variant is equal
to c|log10(MAF)|, where c is estimated assuming that the
maximum OR corresponds to a MAF of 1024. It was assumed
that no logOR for causal variants was negative (results were
broadly consistent if 20% of the causal variants were assumed to
have negative logOR, results not shown). One thousand simula-
tions were run for a region length of 17.7 kb (median of all gene
lengths analysed in the real data), maximum OR of all variants
analysed ranged from 5 to 10, significance (alpha) thresholds of
2.861026 (Bonferroni correction for testing of 18,000 genes) and
0.01 (nominal significance threshold used to define genes as input
to DAVID Gene Ontology analysis) were used and the percentage
of causal variants with MAF,1% (only variants with MAF,1%
were considered causal) given were 25% and 50%.
Power to detect a region of length 17.7 kb with a maximum OR
of 10, assuming that 50% of variants with MAF,1% are causal is
53% for a Bonferroni-corrected significance threshold of
2.861026, and 89% for a nominal significance threshold of 0.01
(Figure S4).
Functional annotation and pathway enrichment analyses
We tested for enrichment of Gene Ontology terms and
enrichment of signals in known biological pathways within the
results of the single-variant, gene-based and case-only analyses.
A total of 150 genes had P,0.01 in the SKAT analyses (of
these, 28 also had P,0.01 in the AMELIA analysis but many
genes were not analysed using both SKAT and AMELIA and so
only SKAT results, which included all SNPs with no MAF cut-off,
were included in this analysis). A total of 1533 genes contained
novel putatively functional variants in the resistant smoker cases.
We tested for enrichment of Gene Ontology categories within
each of these gene lists using DAVID [14] with an EASE (modified
Fisher’s Exact) P,0.05.
We tested for pathway enrichment within the single-variant
association results using MAGENTA v2 [22]. Briefly, MAGENTA
tests for deviation from a random distribution of strengths of
association signals (P values) for each pathway and includes all
available exome-wide single-variant association results
(n = 94,138). Six databases of biological pathways were tested:
including Ingenuity Pathway (June 2008, number of pathways
n = 92), KEGG (2010, n = 186), PANTHER Molecular Function
(January 2010, n= 276), PANTHER Biological Processes (January
2010, n= 254), PANTHER Pathways (January 2010, n= 141) and
Gene Ontology (April 2010, n= 9542). Significance thresholds
were Bonferroni corrected for each database.
Immunohistochemistry
Fixed lung tissue was sectioned and mounted. Slides were treated
in Histo-Clear and then re-hydrated using 100% ethanol and 95%
ethanol washes. Antigen retrieval was carried out by steaming the
tissue samples for 30 minutes in sodium citrate buffer (2.1 g Citric
Acid [Fisons - C-6200-53]+13 ml 2M NaOH [Fisher - S-4880/53]
in 87 ml H2O). Tissue was then treated with peroxidise blocking
solution (Dako - S2023), followed by treatments with a 1 in 50
dilution of rabbit anti-CCDC38 antibody (Sigma HPA039305;
0.2 mg/ml) or a 1 in 50 dilution of the Rabbit IgG Isotype control
(Invitrogen 10500C, diluted to 0.2 mg/ml). Secondary antibody
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staining and DAB treatment was carried out using the EnVision
Detection Systems Peroxidase/DAB, Rabbit/Mouse kit (Dako –
K5007). Tissue was then counterstained with Mayers Hematoxylin
solution (Sigma – 51275) before being dehydrated using 95%
ethanol and 100% ethanol washes. Slides were mounted using
Vectamount (Vector Laboratories - H-5000).
Lung eQTL analysis
The description of the lung eQTL dataset and subject
demographics have been published previously [54–56]. Briefly,
non-tumor lung tissues were collected from patients who
underwent lung resection surgery at three participating sites:
Laval University (Quebec City, Canada), University of Groningen
(Groningen, The Netherlands), and University of British Columbia
(Vancouver, Canada). Whole-genome gene expression and geno-
typing data were obtained from these specimens. Gene expression
profiling was performed using an Affymetrix custom array
(GPL10379) testing 51,627 non-control probe sets and normalized
using RMA [57]. Genotyping was performed using the Illumina
Human1M-Duo BeadChip array. Genotype imputation was
undertaken using the 1000G reference panel. Following standard
microarray and genotyping quality controls, 1111 patients were
available including 409 from Laval, 363 from Groningen, and 339
from UBC. Lung eQTLs were identified to associate with mRNA
expression in either cis (within 1 Mb of transcript start site) or in
trans (all other eQTLs) and meeting the 10% false discovery rate
(FDR) genome-wide significant threshold.
Supporting Information
Figure S1 FEV1/FVC against % predicted FEV1 for the
Gedling and Nottingham Smoker cohorts. The 100 samples
selected as ‘‘resistant smokers’’ are indicated in red. The GOLD
stage 2 thresholds for FEV1/FVC (0.7) and % predicted FEV1
(80%) are indicated.
(TIF)
Figure S2 Mean coverage per resistant smoker sample across
whole exome.
(TIF)
Figure S3 Power to detect single variant associations (analysis 2
in the flowchart, Figure 1) for a range of odds ratios and for
variants frequencies 0.5%, 1% and 3%.
(TIF)
Figure S4 Estimates of power to detect association of a region of
length 17.7 kb in a case-control study using SKAT. Calculations
based on simulations of a study consisting of 100 cases and 166
controls. Power estimates are shown on the y axis for a range of
maximum ORs (5 to 10, x axis). Black bars represent the power
assuming that 50% of all variants with MAF,1% are causal and
the grey bars represent the power assuming 25% of all variants
with MAF,1% are causal (we assume that only variants with
MAF,1% are causal). Figure a) power to detect association
reaching a Bonferroni-corrected significance threshold of
2.661028 and figure b) power to detect association reaching a
nominal significance threshold of 0.01.
(TIF)
Table S1 Sample characteristics. A) Characteristics of 100
resistant smoker samples. B) Characteristics of 230 secondary
control samples. NB: Age, lung function and smoking behaviour
information only available for up to 185 of the 230 samples.
(DOCX)
Table S2 Genes containing 3 novel variants predicted to be
putatively functional (no gene contained more than 3 novel
putatively functional variants).
(DOCX)
Table S3 Novel variants predicted to be putatively functional
and identified in 2 or more samples. The final column gives the
total number of novel variants predicted to be putatively functional
identified in this study in each gene. REF=b37 reference allele,
ALT=non-reference allele. HET=number of heterozygote
individuals. ALT HOM=number of individuals homozygous for
the ALT allele. ALT COUNT= total ALT allele count.
(DOCX)
Table S4 Gene Ontology (GO) terms reaching Bonferroni
corrected significance for enrichment amongst the 1533 genes
harbouring novel putatively functional variants in the resistant
smokers, using DAVID. Ontologies: MF: Molecular Function, BP:
Biological Process, CC: Cellular Component.
(DOCX)
Table S5 Lung eQTL results meeting 10% FDR for rs10859974
(chr12, non-synonymous SNP in CCDC38) proxy SNPs (r2.0.3).
Z.laval, Z.Groningen and Z.UBC are the per-study estimates
which were then meta-analysed. MAF: minor allele frequency. All
SNPs are on chromosome 12. *r2 with rs10859974. #First allele is
eQTL coded/effect allele. (s) = synonymous, (i) = intronic. See
methods.
(DOCX)
Table S6 Single-variant association results using the secondary
controls for the 20 exonic SNPs showing the strongest association
in the resistant smoker cases vs. Edinburgh MR-psychosis control
set. NA: SNP not measured in secondary controls.
(DOCX)
Table S7 Single variant association results for SNPs within
500 kb of rs1051730 (highlighted in bold) in the 15q25.1 region
which has previously shown strong association with smoking
behaviour.
(DOCX)
Table S8 SKAT and AMELIA analysis results using secondary
controls, ranked by SKAT P value. #Only genes with .4 SNPs
with MAF,5% were tested by AMELIA. The P values for
the SKAT and AMELIA analyses when Edinburgh MR-
psychosis controls were used are shown in the last 2 columns.
Genomic control inflation factor was 1 for SKAT and 0.99 for
AMELIA.
(DOCX)
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